Heart medication taken in combination with chemotherapy reduces the risk of serious cardiovascular damage in patients with early-stage breast cancer, according to results from a new landmark clinical trial.
Dec 9, 2015
0
5
Researchers from the University of East Anglia are calling for medical trial data to be kept in national repositories.
Oct 21, 2015
0
8
Sports participation may be safer than previously thought for children with the heart rhythm disorder long QT syndrome, and authors of a new study in JACC: Clinical Electrophysiology say restrictions should be eased to allow ...
Apr 20, 2015
0
8
An investigational treatment for Marfan syndrome is as effective as the standard therapy at slowing enlargement of the aorta, the large artery of the heart that delivers blood to the body, new research shows. The findings ...
Nov 18, 2014
0
0
A novel registry study from Karolinska Institutet in Sweden suggests that beta blockers may benefit also patients suffering from a relatively unknown form of heart failure called HFPEF, which today lacks well-established ...
Nov 16, 2014
0
0
Dialysis patients who take heart medications that are easily removed from the circulation through dialysis may be at increased risk of dying prematurely compared with patients whose heart medications are more difficult to ...
Oct 30, 2014
0
1
(HealthDay)—For patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), beta-blocker therapy at discharge correlates with reduced all-cause mortality, ...
Jun 18, 2014
0
0
Use of beta (β)-blockers in patients who have not had a recent heart attack but were undergoing nonemergency coronary artery bypass grafting (CABG) surgery was not associated with better outcomes.
Jun 16, 2014
0
0
There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to ...
May 28, 2014
0
0
Clinicians have been urged to consider using spironolactone in their patients with heart failure and preserved ejection fraction (HFPEF) after a post-hoc analysis of the TOPCAT trial showed benefit in patients from the Americas.
May 18, 2014
0
0
